Inducible Regulatory T Cell Composition With Stable Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for inducing regulatory T cells from human peripheral T cells result in unstable expression of suppressive molecules and insufficient immunosuppressive activity, limiting their effectiveness in treating T cell-related disorders.
Innovation Solution
A method involving multiple steps of stimulation and dormant culturing of human peripheral T cells using anti-CD3 antibody and IL-2, followed by further stimulation and dormant culturing, to induce regulatory T cells with high expression of FoxP3 and other suppressive molecules, ensuring a stable and functional immunosuppressive effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to induce regulatory T cells from human peripheral T cells, then the induction process is simpler and faster, but the expression of suppressive molecules is unstable and immunosuppressive activity is insufficient
Solution Approach 1:
The induction process is divided into multiple sequential stages: initial activation with anti-CD3 antibody, first dormant culturing period, second stimulation phase, and second dormant culturing period. Each stage serves a specific function in progressively enhancing FoxP3 expression and suppressive molecule stability, transforming a single complex process into manageable segments that collectively achieve reliable Treg induction
Solution Approach 2:
The method employs periodic cycles of stimulation followed by dormant culturing phases. Between stimulation events, cells undergo dormant periods where they consolidate molecular expression without external signals. This rhythmic pattern of activation and rest creates optimal conditions for stable FoxP3 expression and accumulates suppressive molecules throughout the induction process
2Reliability
If multiple stimulation and dormant culturing steps are performed to induce stable regulatory T cells, then immunosuppressive functionality is enhanced, but the induction time and process complexity increase
Solution Approach 1:
The induction protocol maintains continuous productive activity throughout the process by eliminating idle periods. Each dormant culturing phase is immediately followed by another stimulation or culturing step, ensuring that cells are constantly progressing toward mature Treg phenotype. This continuous action maximizes the efficiency of each day of culture and achieves high functionality within the necessary time frame
Solution Approach 2:
The method performs preliminary activation and molecular priming in early stages before final Treg maturation. Initial anti-CD3 stimulation and first dormant period prepare cells by upregulating transcription factors and epigenetic modifiers needed for stable FoxP3 expression. This preliminary preparation ensures that subsequent stimulation phases are more efficient, reducing total induction time while maintaining high reliability
Data Source
AI summary
According to the present disclosure, there is provided a pharmaceutical composition for treating or preventing a T cell-related disorder, the pharmaceutical composition comprising an inducible regulatory T cell having high functionality and stable immunosuppressive function. T cell: The present disclosure provides a pharmaceutical composition for treating or preventing a T cell-related disorder, the pharmaceutical composition comprising, as an active ingredient, an inducible regulatory T cell having at least one feature selected from the group consisting of CTLA4 positivity, NT5E positivity, ITGAE (CD103) positivity, and AREG positivity.